HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan.

AbstractBACKGROUND:
Radioimmunotherapy with radiolabeled monoclonal antibodies to CD20 produces a high response rate in patients with recurring non-Hodgkin lymphoma (NHL), but the durability of those remissions is not well defined.
METHODS:
Data on patients with recurring NHL treated with yttrium Y 90 ibritumomab tiuxetan in 4 clinical trials were reviewed to identify patients with a long-term response, defined as a time to progression of 12 months or longer.
RESULTS:
Long-term responses were seen in 37% (78/211) of patients. At a median follow-up of 53.5 months (range, 12.7-88.9) the median duration of response was 28.1 months and the median time to progression was 29.3 months. A third of these patients had been treated with at least 3 previous therapies, and 37% of them had not responded to their last therapy. The findings in patients with follicular lymphoma (n=59) were similar to those in the overall population of long-term responders. The estimated overall survival at 5 years was 53% for all patients treated with 90Y ibritumomab tiuxetan and 81% for long-term responders.
CONCLUSIONS:
A single dose of 90Y ibritumomab tiuxetan can produce durable responses and prolonged overall survival in a substantial number of patients in whom previous therapies have failed.
AuthorsThomas E Witzig, Arturo Molina, Leo I Gordon, Christos Emmanouilides, Russell J Schilder, Ian W Flinn, Mohamed Darif, Roger Macklis, Katie Vo, Gregory A Wiseman
JournalCancer (Cancer) Vol. 109 Issue 9 Pg. 1804-10 (May 01 2007) ISSN: 0008-543X [Print] United States
PMID17380530 (Publication Type: Clinical Trial, Phase I, Clinical Trial, Phase II, Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial)
CopyrightCopyright (c) 2007 American Cancer Society
Chemical References
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Agents
  • Immunoconjugates
  • Yttrium Radioisotopes
  • Rituximab
  • ibritumomab tiuxetan
Topics
  • Antibodies, Monoclonal (therapeutic use)
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Agents (therapeutic use)
  • Drug Resistance, Neoplasm
  • Humans
  • Immunoconjugates (therapeutic use)
  • Lymphoma, B-Cell (drug therapy, mortality, radiotherapy)
  • Neoplasm Recurrence, Local (drug therapy, mortality)
  • Radioimmunotherapy (methods)
  • Rituximab
  • Yttrium Radioisotopes (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: